Financial Express (Holdings) Limited (“we”, “our”, “us” and derivatives) are committed to protecting and respecting your privacy. This Privacy Policy, together with our Terms of Use, sets out the basis on which any personal data that we collect from you, or that you provide to us, will be processed by us relating to your use of any of the below websites (“sites”).


For the purposes of the Data Protection Act 1998, the data controller is Trustnet Limited of 2nd Floor, Golden House, 30 Great Pulteney Street, London, W1F 9NN. Our nominated representative for the purpose of this Act is Kirsty Witter.


We collect information about you when you register with us or use any of our websites / services. Part of the registration process may include entering personal details & details of your investments.

We may collect information about your computer, including where available your operating system, browser version, domain name and IP address and details of the website that you came from, in order to improve this site.

You confirm that all information you supply is accurate.


In order to provide personalised services to and analyse site traffic, we may use a cookie file which is stored on your browser or the hard drive of your computer. Some of the cookies we use are essential for the sites to operate and may be used to deliver you different content, depending on the type of investor you are.

You can block cookies by activating the setting on your browser which allows you to refuse the setting of all or some cookies. However, if you use your browser settings to block all cookies (including essential cookies) you may not be able to access all or part of our sites. Unless you have adjusted your browser setting so that it will refuse cookies, our system will issue cookies as soon as you visit our sites.


We store and use information you provide as follows:

  • to present content effectively;
  • to provide you with information, products or services that you request from us or which may interest you, tailored to your specific interests, where you have consented to be contacted for such purposes;
  • to carry out our obligations arising from any contracts between you and us;
  • to enable you to participate in interactive features of our service, when you choose to do so;
  • to notify you about changes to our service;
  • to improve our content by tracking group information that describes the habits, usage, patterns and demographics of our customers.

We may also send you emails to provide information and keep you up to date with developments on our sites. It is our policy to have instructions on how to unsubscribe so that you will not receive any future e-mails. You can change your e-mail address at any time.

In order to provide support on the usage of our tools, our support team need access to all information provided in relation to the tool.

We will not disclose your name, email address or postal address or any data that could identify you to any third party without first receiving your permission.

However, you agree that we may disclose to any regulatory authority to which we are subject and to any investment exchange on which we may deal or to its related clearing house (or to investigators, inspectors or agents appointed by them), or to any person empowered to require such information by or under any legal enactment, any information they may request or require relating to you, or if relevant, any of your clients.

You agree that we may pass on information obtained under Money Laundering legislation as we consider necessary to comply with reporting requirements under such legislation.


We want to ensure that the personal information we hold about you is accurate and up to date. You may ask us to correct or remove information that is inaccurate.

You have the right under data protection legislation to access information held about you. If you wish to receive a copy of any personal information we hold, please write to us at 3rd Floor, Hollywood House, Church Street East, Woking, GU21 6HJ. Any access request may be subject to a fee of £10 to meet our costs in providing you with details of the information we hold about you.


The data that we collect from you may be transferred to, and stored at, a destination outside the European Economic Area (“EEA”). It may be processed by staff operating outside the EEA who work for us or for one of our suppliers. Such staff may be engaged in, amongst other things, the provision of support services. By submitting your personal data, you agree to this transfer, storing and processing. We will take all steps reasonably necessary, including the use of encryption, to ensure that your data is treated securely and in accordance with this privacy policy.

Unfortunately, the transmission of information via the internet is not completely secure. Although we will do our best to protect your personal data, we cannot guarantee the security of your data transmitted to our sites; any transmission is at your own risk. You will not hold us responsible for any breach of security unless we have been negligent or in wilful default.


Any changes we make to our privacy policy in the future will be posted on this page and, where appropriate, notified to you by e-mail.


Our sites contain links to other websites. If you follow a link to any of these websites, please note that these websites have their own privacy policies and that we do not accept any responsibility or liability for these policies. Please check these policies before you submit any personal data to these websites.


If you want more information or have any questions or comments relating to our privacy policy please email [email protected] in the first instance.

 Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Tuesday 07 October, 2008

Summit Corporation PLC

Re Agreement for Tuberculosis Programme

Summit Corporation plc
("Summit plc" or "the Company")


Oxford, UK, 7 October 2008  - Summit Corporation  plc (AIM: SUMM),  a
leading UK biotechnology company, announces today that it has entered
into a  co-development agreement  for  its early  stage  tuberculosis
("TB") programme  with  the Lilly  TB  Drug Discovery  Initiative,  a
public-private partnership created by the pharmaceutical company  Eli
Lilly and Company (NYSE: LLY) to discover and develop new early stage
TB drug candidates.

Under the  terms  of  the  agreement, the  Lilly  TB  Drug  Discovery
Initiative ("Initiative")  will  have  an exclusive  licence  to  the
compounds discovered by Summit  in the developing  world and will  be
responsible  for  future  research  and  development  costs.   Summit
retains all rights in the developed world to these compounds for  the
treatment of TB and  all other indications, and  will have access  to
any data generated  during the  development of  the programme.  These
data  can  be  used  by  Summit  as  part  of  future   sub-licensing
agreements.  Summit will be a key member of a joint development  team
and will  therefore maintain  close  involvement in  the  programme's
future scientific development.

Steven Lee, PhD,  Chief Executive Officer  of Summit commented:  "The
signing of this agreement with the Lilly TB Drug Discovery Initiative
is an exciting development for our TB programme and Summit is pleased
to be working with  some of the world's  leading drug researchers  in
the field of infectious diseases through this partnership.  I believe
this agreement  will  give our  novel  class of  compounds  the  best
opportunity of  being  developed  into  a  new  and  urgently  needed
medicine for the benefit of TB patients around the world.

 "This agreement highlights the  continued progress Summit is  making
in fulfilling its  strategy of  signing early  stage programme  deals
that immediately remove  costs from the  business while retaining  an
interest in their future success.  Through our innovative  technology
platforms in carbohydrate chemistry and zebrafish biology, Summit has
the assets  to maintain  the  strength of  our  drug pipeline  and  I
anticipate the signing of further agreements in the coming months."

Background to the Lilly TB Drug Discovery Initiative and Summit's  TB

TB remains a serious global health  issue with over one third of  the
World's population suspected to be infected with the disease, and  is
one of  the leading  causes  of death  in  the developing  world.  In
addition, TB has once again become a significant healthcare threat in
the developed world. It is over 30 years since the last new  medicine
to treat TB was launched and there is an increasingly urgent need for
the development  of  new  medicines.  The  Lilly  TB  Drug  Discovery
Initiative has been created and funded by Lilly with the ambition  of
developing new  clinical  candidates  for  TB  medicines.  The  other
members of the  Initiative include the  Infectious Diseases  Research
Institute (IDRI) and the National Institute of Allergy and Infectious
Diseases (NIAID), part of the US National Institutes of Health (NIH).

Summit's TB programme is based on a novel class of compounds that has
shown excellent  levels of  in  vitro cell-killing  activity  against
Mycobacterium  tuberculosis,  the  bacteria   that  causes  TB.   The
compounds act  via  a mode  of  action  distinct from  all  other  TB
therapies.  Significantly, the compounds are also active against both
multi-drug resistant bacterial  strains and the  dormant form of  the
bacteria emphasising  their potential  ability to  shorten  treatment
regimes (a key issue with current  therapies) and as a treatment  for
latent TB infection.

                              - ENDS -

For more information, please contact:
Summit plc
Steven Lee, PhD, Chief Executive Officer
Richard Pye, PhD, Investor Relations
Tel: +44 (0)1235 443951; +44 (0)7825 313476
Citigate Dewe Rogerson
Mark Swallow, PhD / David Dible / Emma Palmer Foster
Tel: +44 (0)207 638 9571
Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc  is  a  leading  UK biotechnology  company  with  a  broad
preclinical  and  clinical  pipeline,  two  world-leading  technology
platforms and  an  innovative  business model  that  is  expected  to
generate sustainable value for investors.
Summit is  developing  multiple  drug programmes  that  target  unmet
medical  needs  from   which  it   intends  to   generate  value   by
out-licensing attractive  late preclinical  or early  clinical  stage
programmes in  return for  upfront, milestone  and royalty  payments.
Summit uses  its  scientific  expertise to  target  orphan  diseases,
neuro-disorders and infectious  diseases. Summit has  signed a  major
licensing agreement with BioMarin in Duchenne muscular dystrophy  and
has co-development  agreements  with  Evolva  (infectious  diseases),
Orient  Pharma  (sialorrhoea)  and   the  Lilly  TB  Drug   Discovery
Initiative (tuberculosis)
Underpinning Summit's  drug pipeline  are two  innovative  technology
platforms:  carbohydrate  chemistry  and  zebrafish  biology.   These
platforms support existing programmes and also will be the source  of
future  programmes  to  replenish  Summit's  drug  pipeline.    These
platform technologies also form the basis of the Company's profitable
service business.
The company listed on the alternative investment market (AIM) of  the
London Stock  Exchange  in  October 2004  -  symbol:  SUMM.   Further
information about the company is available at

About The Lilly TB Drug Discovery Initiative
The  Lilly  TB   Drug  Discovery  Initiative   is  a   not-for-profit
public-private partnership with a  mission to accelerate  early-stage
drug discovery by bringing together specialists from around the world
for the systematic exploration  of vast, private molecular  libraries
in search of new TB treatments.  Headquartered in Seattle, The  Lilly
TB Drug Discovery Initiative  includes representatives of  government
agencies,  philanthropic  organizations,  pharmaceutical   companies,
universities and  other research  institutions.  Its  most  important
goal is filling the pipeline for future TB drugs.
About Lilly
Lilly, a  leading  innovation-driven  corporation,  is  developing  a
growing portfolio of first-in-class and best-in-class  pharmaceutical
products by  applying  the latest  research  from its  own  worldwide
laboratories  and   from  collaborations   with  eminent   scientific
organizations. Headquartered  in Indianapolis,  Ind., Lilly  provides
answers - through medicines and information - for some of the world's
most urgent  medical needs.  Additional  information about  Lilly  is
available at
For this Initiative, Lilly has opened access to its greatest  assets,
a library  of 500,000  compounds.  The company  also is  lending  its
immense drug  discovery expertise  and organizational  savvy, and  is
contributing the latest,  most innovative technologies  used in  drug
discovery to be applied to the search for new drugs to fight TB.  The
$15 million Lilly has given  to support this historic undertaking  is
part   of    Lilly's    $135   million    commitment    to    control
multidrug-resistant TB through  The Lilly  MDR-TB Partnership,  which
mobilizes 18 partners on  five continents to stop  the spread of  the
disease and  save  lives.  Additional information  can  be  found  at

About IDRI
IDRI is  a  Seattle-based not-for-profit  organization  committed  to
applying innovative  science  to  the  research  and  development  of
products to prevent, detect and treat infectious diseases of poverty.
By integrating  capabilities, IDRI  strives  to create  an  efficient
pathway bringing scientific innovation from the lab to the people who
need it most. For more information, go to

NIAID conducts and supports research - at NIH, throughout the  United
States, and  worldwide  -  to  study the  causes  of  infectious  and
immune-mediated diseases, and to develop better means of  preventing,
diagnosing and treating these  illnesses. News releases, fact  sheets
and  other  materials  are  available  on  the  NIAID  Web  site   at
NIH - The Nation's Medical  Research Agency - includes 27  Institutes
and Centers and is a component of the U. S. Department of Health  and
Human Services. In  fiscal year  2007, NIAID invested  more than  $47
million in almost 90 projects  focused on TB drug development.  NIAID
also offers a wide variety of fundamental research, preclinical,  and
clinical development  resources  that  can be  leveraged  to  further
develop prioritized and validated molecular candidates and assist  in
transitioning them into clinical testing.



a d v e r t i s e m e n t